NEURACAP
Sector OutlookPublished · 22 pages · Free to read

Hospitals and Health Systems Sector Outlook — September 2026

This report reviews the Hospitals and Health Systems sector as of September 28, 2026, comparing 8 listed operators on EV/EBITDA (CY2027E) and setting recent precedent transaction multiples alongside the public peer range.

For information only. Not an appraisal or a fairness opinion.

What moved since: Hospitals and Health Systems M&A update, 14–28 September 2026

Key figures

Sector median EV/EBITDA (CY2027E)
6.8x
8 rated companies
Higher-margin cohort multiple
8.3x
Above 20% EBITDA margin
Lower-margin cohort multiple
5.2x
Below 20% EBITDA margin
Precedent deal multiple, high end
9.8x
LTM at announcement

Read the report

NeuraCap

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › HOSPITALS AND HEALTH SYSTEMS

Hospitals: Profitability Is Where the Price Gap Sits

How the listed hospital operators are priced today on forward EBITDA, what recent transactions cleared, and where the spread inside one classification actually sits.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E)

Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice

1

1 / 22

Executive summary

Across the 8 listed hospital operators, EV/EBITDA (CY2027E) carries a sector median of 6.8x, and the higher multiples sit with the slower-growing names rather than the faster ones. Profitability separates the set more sharply than growth: names above the 20% margin line carry 8.3x against 5.2x below it. Recent precedent transactions cleared from 7.2x to 9.8x, above the listed middle, with regional systems and operators dominant among recent buyers and sellers.

Key findings

  • Higher hospital valuations track slower revenue growth, not faster growth.
  • Profitability splits the peer set more sharply than growth does (8.3x vs 5.2x).
  • Margins range from 8% to 29% across the 8 listed operators, far wider than growth.
  • Recent precedent deals cleared from 7.2x to 9.8x, above the listed sector median.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › HOSPITALS AND HEALTH SYSTEMS

    This is the cover page introducing the Hospitals and Health Systems sector outlook as of September 28, 2026.

    We're opening with the Hospitals and Health Systems sector as of September 28, 2026, valued primarily on EV/EBITDA for CY2027E. The pages that follow show where pricing sits across the listed peer set and what recent transactions have cleared.

    Everything on this page

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › HOSPITALS AND HEALTH SYSTEMS Hospitals: Profitability Is Where the Price Gap Sits How the listed hospital operators are priced today on forward EBITDA, what recent transactions cleared, and where the spread inside one classification actually sits. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E) Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    This slide lists the report's five sections plus an appendix.

    We've structured this report in five sections plus an appendix, starting with the bottom line so a reader who stops there still gets the whole story. From there we move through the landscape, valuation and situations, precedent transactions, and strategic implications, each building on the last.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line One Hospital Classification, and a Price Band That Runs Wide Inside It 02 The Landscape Behavioural and Specialty Hospital Facilities Is the Whole Peer Set Here 03 Valuation & Situations Two Operators Hold the Top of the Range and Two Sit at the Bottom 04 Precedent Transactions Buyers Have Been Paying Above the Listed Middle for Hospital Platforms 05 Strategic Implications What to Work on While the Price Band Stays This Wide 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Hospitals and Health Systems: One Facilities Group on the Screen, and the Higher Prices Sit with the Slower Growers

    This slide presents the report's central finding that higher valuations sit with slower-growing hospital operators.

    We anchor this report on EV / EBITDA (CY2027E) across all 8 eligible companies, with market data as of September 28, 2026, and a sector median of 6.8x. Across this peer set, the higher valuations sit with the slower-growing names rather than the faster ones. That's the single finding the rest of the deck unpacks in detail, so what matters here is the direction of the spread, not the size of the peer set.

    Everything on this page

    01 · THE BOTTOM LINE Hospitals and Health Systems: One Facilities Group on the Screen, and the Higher Prices Sit with the Slower Growers The full story on one page · figures on EV / EBITDA (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (8 of 8 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 One Label Covers the Whole Screen — the Comparison Is Name by Name 8 of the 8 approved names sit in behavioural and specialty hospital facilities, and 8 of the 8 carry a CY2027E EBITDA estimate. The middle of the set is 6.8x forward EV / EBITDA, with the middle band running from 5.5x to 8.2x — one label, a wide price band inside it. 2 The Faster-Growing Half Carries the Lower Price Split the 8 listed hospital operators at 4% revenue growth and the slower half sits at 7.6x on CY2027E EBITDA against 6.0x for the faster half, 4 names each side. A forward multiple already credits the growth in the forecast, and on this set the premium still sits with the slower half rather than with the faster one. 3 A Wide Margin Spread Puts Earnings Quality in Play Reported EBITDA margins across the 8 run from 8% to 29%, a far wider spread than revenue growth shows. With core inpatient rates administered rather than negotiated, how much of that margin rests on commercially contracted volume versus supplemental payment programmes is a question the earnings profile itself raises in diligence. 4 Recent Transactions Have Cleared Above the Listed Middle Across the 9 transactions shown, disclosed EBITDA multiples run from 7.2x to 9.8x, a band that sits above the middle of the 8 listed hospital operators. Not-for-profit and regional systems appear as buyers and sellers in that record, so that band is associated with local density. 6.8x Sector median EV/EBITDA CY2027E consensus · 8 rated of 8 companies 9.9x Premium end EV/EBITDA vs 4.6x at the discount end top quartile (n=2) against bottom quartile (n=2) on EV/EBITDA — the spread the report explains 17 Transactions with disclosed terms 45 recorded in this tier · 1 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    This divider introduces Section 02 on the market landscape.

    Section 02 turns to the landscape: how the peer set breaks down and where the comparison actually needs to be made. We compare operator against operator here, not segment against segment, since one classification covers the whole screen.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE Behavioural and Specialty Hospital Facilities Is the Whole Peer Set Here The comparison that matters runs operator against operator, not segment against segment. 02 of 06 Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    One Classification Covers the Whole Screen, so Value Is Judged Name by Name

    This slide groups the 8 approved companies by business segment and shows median EV/EBITDA (CY2027E) per group.

    We've grouped all 8 approved companies by business segment and calculated the median EV / EBITDA (CY2027E) for each group as of September 28, 2026. Because one classification covers the whole peer set, the segment view doesn't do the differentiating work — the real spread sits between individual operators. So the question worth asking of any name on this page is not which group it sits in, but where it lands inside that group.

    Everything on this page

    02 · MARKET MAP One Classification Covers the Whole Screen, so Value Is Judged Name by Name 8 approved companies grouped by business segment · median EV / EBITDA (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 BEHAVIORAL AND SPECIALTY HOSPITAL FACILITIES 8 cos median 6.8x HCA Healthcare (HCA) Tenet Healthcare (THC) Encompass Health (EHC) Universal Health (UHS) Community Health (CYH) Ardent Health (ARDT) Nutex Health (NUTX) Auna S.A. (AUNA) This is the entire peer set — 8 of the 8 operators sit here, so relative value is argued operator against operator rather than segment against segment.

  6. 06
    02 · LANDSCAPE

    One Group on the Table, and the Spread Inside It Is Where the Story Sits

    This slide presents the segment view of the approved universe with EV/EBITDA (CY2027E) medians on rated names.

    This page lays out the segment view of the approved universe, with EV / EBITDA (CY2027E) medians calculated only on the names that carry a rating. With one segment covering the whole set, the spread inside that single group is where the real signal sits. Full company-level detail is available in the appendix, so this page is the summary view a client can act on quickly.

    Everything on this page

    02 · LANDSCAPE One Group on the Table, and the Spread Inside It Is Where the Story Sits Segment view of the approved universe · EV / EBITDA (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/EBITDA Names to know What they do — and why it matters Behavioral and specialty hospital facilities 8 100% 6.8x HCA Healthcare, Inc. (HCA) · Tenet Healthcare Corporation (THC) · +6 more One label, the whole set. 8 of the 8 approved names sit here — 100% of the screen — and the middle of the group is 6.8x forward EV / EBITDA on CY2027E. Inside one label sit operators of different shape: acute hubs with ambulatory rings, post-acute rehabilitation and physician-aligned formats. That is why buyers underwrite facility-level EBITDA and build value up from there, rather than pricing the label.

  7. 07
    SECTION 03

    03

    This divider introduces Section 03 on public market valuation.

    Section 03 turns to valuation: two operators hold the top of the range, and two sit at the bottom, all on EV / EBITDA (CY2027E) with all 8 names carrying an estimate.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS Two Operators Hold the Top of the Range and Two Sit at the Bottom Forward EV / EBITDA on CY2027E, with 8 of the 8 names on the page carrying an estimate. 03 of 06 Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    Two Operators Hold the Top of the Range; Two Sit at the Bottom

    This slide ranks all 8 rated companies by EV/EBITDA (CY2027E) and shows the sector median.

    We rank all 8 rated companies by EV / EBITDA (CY2027E), sorted descending, against a sector median of 6.8x as of September 28, 2026. Two operators hold the top of the range and two sit at the bottom, with tier zones cut at the rated set's own quartiles. That spread is the starting point for everything that follows, so the question becomes what separates the top tier from the bottom.

    Everything on this page

    03 · PUBLIC MARKET VALUATION Two Operators Hold the Top of the Range; Two Sit at the Bottom EV / EBITDA (CY2027E) · all 8 rated companies, sorted descending · sector median 6.8x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (8 of 8 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / EBITDA (CY2027E) basis. Panel commentary is a NeuraCap view. Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 9.9x CORE · median 6.8x DISCOUNT · median 4.6x Sector median 6.8x WHAT SEPARATES THE TWO ENDS The top pair trades on durability. Encompass Health Corporation (EHC) and HCA Healthcare, Inc. (HCA) sit at 9.9x on CY2027E EBITDA. Both run multi-market platforms with depth in high-acuity service lines and an established position in their defined service areas, which is the profile buyers say they underwrite. The bottom pair carries open questions. Ardent Health Inc. (ARDT) and Auna S.A. (AUNA) sit at 4.6x. At this end of the range the questions that get asked are concentration in a single platform or geography, how much of the margin base depends on programme renewal, and what catch-up capex the plant needs. A forward lens already credits growth. Because the multiple is set on CY2027E earnings, the forecast is already in the price. A premium that survives that lens is the market paying for durability of the earnings base rather than for a number in next year's plan — which is where an owner's own case has to be made.

  9. 09
    03 · VALUATION DRIVERS

    Profitability Separates the Two Ends: Names Above the 20% Margin Line Carry 8.3x Against 5.2x Below It

    This slide splits the rated companies by revenue growth and by EBITDA margin to show which driver aligns with valuation.

    We split the rated names into growth and margin cohorts at their covered medians. Names above the 20% margin line carry a median of 8.3x on EV / EBITDA (CY2027E), against 5.2x for names below it — a wider gap than the growth split shows. This is an association in the data we're showing, not a causal claim, but it tells us where to focus diligence: profitability tracks price more closely than growth does on this set.

    Everything on this page

    03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 20% Margin Line Carry 8.3x Against 5.2x Below It Median EV / EBITDA (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=4; slower n=4; higher-margin n=4; lower-margin n=4). Driver readings are NeuraCap views on the supplied data — association, not causation. Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/EBITDA, median per cohort · growth split at 4% · EBITDA-margin split at 20% Split at 4% Growth, the Slower Half Prices Higher Split the 8 listed hospital operators at 4% revenue growth and the slower half sits at 7.6x forward EV / EBITDA, against 6.0x for the faster half, with 4 names on each side. On a set this size that is an association rather than a mechanism, but it says pace alone is not what the market is rewarding here. Clearing the Margin Bar Travels with the Higher Multiples On the 2 names above the margin bar but below the growth bar, the multiple sits at 8.3x; on the 2 names above the growth bar but below the margin bar, it sits at 5.2x. That ordering matches how buyers price facilities — off adjusted facility EBITDA, with rent and minority economics taken out first. Reported Margins Run Far Wider than Growth Does Reported EBITDA margins across the 8 run from 8% at Ardent Health Inc. (ARDT) to 29% at Nutex Health, Inc. (NUTX), a wider spread than the growth estimates show. Payer mix, negotiated commercial rate position and contract labour reliance are the first places to look when a gap that wide opens up. Programme Renewals Sit on the Earnings Base, Not the Growth Line Supplemental payment, state directed payment and provider fee income carry renewal risk that buyers rarely capitalise on the same basis as commercially contracted volume. Two operators with identical reported margin can be underwritten very differently once that split in the base is worked through.

  10. 10
    03 · SITUATION MAP

    3 of the 8 Hold a Premium Price on Slower Growth

    This slide maps the 8 companies on EV/EBITDA versus the sector median and revenue growth versus the covered median.

    We cut the 8 rated companies on EV / EBITDA against the 6.8x sector median, and on revenue growth against the 4% covered median. Three of the eight hold a premium price on slower growth — the situation this report is built around. These are observations on where each operator sits, not recommendations, so what a client does with a position in that quadrant is the next conversation.

    Everything on this page

    03 · SITUATION MAP 3 of the 8 Hold a Premium Price on Slower Growth Cut on EV / EBITDA vs the sector median (6.8x) (rows) and revenue growth vs the covered median (4%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Above the Middle on Price and Growth Above-median multiple · above-median revenue growth 1 names Encompass Health Corporation (EHC) Encompass Health Corporation (EHC) is the single name above the middle of the group on both price and revenue growth. On a cell of one, treat it as a reference point for what a durable earnings base plus pace looks like in this set, not as a rule. Premium Price, Slower Growth Above-median multiple · below-median revenue growth 3 names HCA Healthcare, Inc. (HCA) · Tenet Healthcare Corporation (THC) · Community Health Systems, Inc. (CYH) Three of the 8 sit here: HCA Healthcare, Inc. (HCA), Tenet Healthcare Corporation (THC) and Community Health Systems, Inc. (CYH). Buyers are paying above the middle of the group without the faster growth, so the case rests on position in defined service areas, commercial mix and service-line depth. Below on Price, Faster Growth Below-median multiple · above-median revenue growth 3 names Universal Health Services, Inc. (UHS) · Nutex Health, Inc. (NUTX) · Auna S.A. (AUNA) Universal Health Services, Inc. (UHS), Nutex Health, Inc. (NUTX) and Auna S.A. (AUNA) are growing faster than the middle of the group and priced below it. This is where earnings-quality questions usually live — programme dependence in the base, concentration in one geography, and contract labour reliance. Below the Middle on Both Below-median multiple · below-median revenue growth 1 names Ardent Health Inc. (ARDT) Ardent Health Inc. (ARDT) sits below the middle of the group on both price and revenue growth. On a single name, read it as a prompt to work through the margin base and payer mix rather than as a settled view of the business.

  11. 11
    03 · GROWTH VS PROFITABILITY

    2 of the 8 Clear Both Bars: Growth and Margin Together

    This slide plots revenue growth against EBITDA margin for the 8 companies with both estimates, with median EV/EBITDA per quadrant.

    We plot revenue growth against EBITDA margin for all 8 companies with both estimates, cut at the covered medians of 4% growth and 20% margin. Two of the eight clear both bars together, combining growth and margin in the same name. That combination is rare in this set, so it's worth understanding what those two operators are doing differently before drawing conclusions about the rest of the field.

    Everything on this page

    03 · GROWTH VS PROFITABILITY 2 of the 8 Clear Both Bars: Growth and Margin Together Revenue growth (CY2027E, x-axis) vs EBITDA margin (CY2027E, y-axis) · 8 companies with both estimates · cuts at the covered medians (4% growth, 20% margin) · median EV/EBITDA per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful EV/EBITDA (balanced n=2; margin-only n=2; growth-only n=2; neither n=2). Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 0% 2% 4% 6% 8% 10% 10% 15% 20% 25% 30% MARGIN ONLY median 8.3x BALANCED median 8.4x NEITHER median 6.3x GROWTH ONLY median 5.2x CYH THC HCA ARDT UHS AUNA EHC NUTX x: revenue growth (CY2027E) · y: EBITDA margin (CY2027E) HOW TO READ THIS The map splits the 8 listed hospital operators on the same growth line used through this deck and on a 20% EBITDA margin bar. Encompass Health Corporation (EHC) and Nutex Health, Inc. (NUTX) clear both and sit at 8.4x; the 2 names clearing margin alone sit at 8.3x, the 2 clearing growth alone at 5.2x, and the 2 clearing neither at 6.3x. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 0 of 8 names clear it.

  12. 12
    03 · THE AGENDA

    Three Operating Choices That Sit Alongside the Top of the Hospital Price Range

    This slide sets out three operating choices that sit alongside the top of the hospital price range, framed as questions for an owner or acquirer.

    We frame three operating choices that line up with the top of this price range, put as the questions an owner or acquirer should be resolving. These are NeuraCap observations grounded in the cohort data shown earlier, not recommendations to act. They set the agenda for the strategic implications discussed later in this report.

    Everything on this page

    03 · THE AGENDA Three Operating Choices That Sit Alongside the Top of the Hospital Price Range NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Deepen Density in the Service Areas You Already Hold Local share is what gives a negotiated commercial rate position, and the recorded transactions have been bought for density in defined markets rather than for total bed count. Adding share where you already have an acute hub is the cheaper route to the same payer leverage. What changes the answer: Same-facility adjusted admissions moving one way while commercial mix moves the other. Own the Ambulatory Ring Around the Acute Hub Outpatient migration is already in motion, and the operators priced at the upper end of this set are the ones with the ambulatory and specialty footprint built around inpatient capacity. Build-versus-buy on surgery capacity and physician alignment is the live capital allocation question. What changes the answer: Outpatient volume growing while inpatient case mix index flattens in your core markets. Reduce How Much of the EBITDA Base Depends on a Renewal Supplemental and state directed payment income is examined separately by buyers and is rarely capitalised on the same basis as commercially contracted volume. Shifting mix toward contracted commercial acuity, and taking agency reliance out of the cost base, changes what the base is worth. What changes the answer: A state programme entering its renewal cycle, or a shift in directed payment approval.

  13. 13
    SECTION 04

    04

    This divider introduces Section 04 on precedent transactions.

    Section 04 turns to precedent transactions: recent hospital deals have cleared above the listed middle. Regional systems, operators and one financial sponsor appear across the recorded record.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Buyers Have Been Paying Above the Listed Middle for Hospital Platforms Regional systems, operators and one financial sponsor across the recorded transactions. 04 of 06 Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13

  14. 14
    04 · DEAL CASE STUDIES

    Precedent Hospital Transactions Set a Second Price Benchmark Alongside the Public Peers

    This slide tells one precedent hospital transaction as a case study against the wider set of recorded deals.

    We walk through one of 17 disclosed-terms transactions as a case study, with multiples measured on LTM financials at announcement where disclosed. That deal, and the wider precedent set, sets a second price benchmark alongside the public peer comparison. Deal multiples on this LTM basis aren't directly comparable to the CY2027E public basis, so we're not claiming a spread between the two — only showing where recent deals actually cleared.

    Everything on this page

    04 · DEAL CASE STUDIES Precedent Hospital Transactions Set a Second Price Benchmark Alongside the Public Peers 1 of 17 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 52 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 28 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 Jul-2026 $1.1B Intermountain Health Intermountain Health commits $1.1B for a two-hospital package in one service area EV / LTM revenue n/a EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The buyer is a regional system and the targets are two hospitals in the same local market, which points to completing a referral network inside a defined service area rather than adding national bed count. Deals in this shape usually come with negotiated community commitments — capital investment undertakings and service line continuation — alongside the price. HOW THE TARGET WAS VALUED The disclosed value is $1.1B for the pair, recorded as pending in July 2026. For an owner, it is the clearest recent marker of what a regional system will commit for local density in a single service area, and it sits among the larger recorded transactions in this set.

  15. 15
    SECTION 05

    05

    This divider introduces Section 05 on strategic implications.

    Section 05 turns to strategic implications: what to work on while the price band stays this wide. These are operating moves that sit alongside the higher end of the range.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS What to Work on While the Price Band Stays This Wide Operating moves that sit alongside the higher end of the range, and the evidence to watch. 05 of 06 Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15

  16. 16
    05 · STRATEGIC IMPLICATIONS

    Revenue Mix and Margin Are Where Owners Have Room While the Price Band Stays This Wide

    This slide sets out the strategic questions the data puts on the table for owners over the next twelve months.

    Revenue mix and margin are where we see owners have room while this price band stays as wide as it is. These are NeuraCap views drawn from the analysis in this report — observations, not recommendations. They're the questions worth putting on the table with the operating team over the next twelve months.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS Revenue Mix and Margin Are Where Owners Have Room While the Price Band Stays This Wide NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS The Upper End of This Range Is Held on Margin Durability Across the 8 listed hospital operators the price separation lines up with reported profitability more closely than with pace. The operating levers are payer and acuity mix, negotiated rate position, nurse staffing and agency reliance, and service-line depth around the acute hub. FOR BOARDS Know How Much of Next Year's EBITDA Needs Something Renewed Programme renewal cycles, rent obligations from sale-leaseback structures and joint venture minority economics all change what a buyer would underwrite from the same reported number. Those three lines are worth resolving before any capital commitment is made against them. FOR ACQUIRERS Local Density Is What the Recent Record Has Been Paying For Regional systems and multi-facility operators dominate the recorded transactions, buying clusters inside existing service areas. Price is customarily set on facility-level EBITDA adjusted for rent and minority economics, while the regulatory path — change of ownership, certificate of need, state review — shapes timing.

  17. 17
    SECTION 06

    06

    This divider introduces Section 06 covering the full universe, methodology and sources.

    Section 06 closes with the full universe, methodology and sources behind every figure in this report.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17

  18. 18
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier

    This slide lists all 8 rated companies on EV/EBITDA (CY2027E), grouped by valuation tier.

    This appendix carries all 8 rated companies on EV / EBITDA (CY2027E), shaded against the 6.8x sector median and grouped by valuation tier. Every row here also appears in the companion workbook, which carries the complete field set. It's the reference page for tracing any multiple used earlier in this report back to its source.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/EBITDA above the sector median (6.8x); amber marks below · 8 rated companies · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 8 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/EBITDA (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥8.2x · median 9.9x · 2 companies Encompass Health Corporation EHC Behavioral and specialty hospital facilities $15.8B 10.6x 8% 21% 30 HCA Healthcare, Inc. HCA Behavioral and specialty hospital facilities $148B 9.1x 4% 20% 24 CORE — 5.5x–8.2x · median 6.8x · 4 companies Community Health Systems, Inc. CYH Behavioral and specialty hospital facilities $10.7B 7.9x 1% 12% 13 Tenet Healthcare Corporation THC Behavioral and specialty hospital facilities $36.5B 7.4x 1% 22% 23 Nutex Health, Inc. NUTX Behavioral and specialty hospital facilities $1.7B 6.1x 11% 29% 40 Universal Health Services, Inc. UHS Behavioral and specialty hospital facilities $15.8B 5.8x 5% 14% 19 DISCOUNT — <5.5x · median 4.6x · 2 companies Ardent Health Inc. ARDT Behavioral and specialty hospital facilities $2.4B 4.6x 4% 8% 12 Auna S.A. AUNA Behavioral and specialty hospital facilities $1.4B 4.6x 6% 20% 26

  19. 19
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This slide lists precedent transactions with disclosed terms, newest first.

    This page lists 17 disclosed-terms transactions in this tier, out of 45 recorded, newest first, with multiples on LTM financials at announcement where disclosed. Some of these records carry data-quality flags, and transactions without a disclosed value or multiple sit in the companion workbook rather than here. This is the evidence base behind the transaction benchmark used earlier in this report.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 17 transactions with disclosed terms in this tier (45 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 52 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 28 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Jul-2026 Intermountain Health → Mountain View Hospital and Idaho Falls Community Hospital $1.1B n/a n/a Intermountain Health and the two-hospital package of Mountain View Hospital and Idaho Falls Community Hospital, recorded at $1.1B in July 2026 and shown as pending. Not-for-profit regional systems remain the recurring counterparty, completing referral networks inside… Mar-2026 Freeman Health System → four Arkansas hospitals n/a n/a 8.9x Freeman Health System completed the purchase of four Arkansas hospitals at 8.9x EBITDA in March 2026. A multi-hospital cluster in adjacent geography is the format that has been clearing at the upper end of the recorded transactions. Jul-2024 WoodBridge Healthcare, Inc. → Community Health Systems, Inc. n/a 0.9x 7.9x A completed July 2024 transaction with WoodBridge Healthcare, Inc. as buyer and Community Health Systems, Inc. as target, recorded at 7.9x EBITDA and 0.9x revenue. Divesting campuses outside the core geography is a standing feature of this sector's deal flow. Jul-2021 Cano Health, Inc. → Doctors Medical Center of Modesto, Inc. n/a 1.5x n/a Cano Health, Inc. announced the acquisition of Doctors Medical Center of Modesto, Inc. in July 2021, recorded at 1.5x revenue. A physician-aligned buyer taking on a facility points to referral capture and alignment rather than bed count. Jun-2021 Cano Health, Inc. → University Health Care n/a 1.7x n/a Cano Health, Inc. announced the purchase of University Health Care in June 2021 at 1.7x revenue. Two transactions from the same buyer in consecutive months suggest a build-out of a local care network around existing patient panels. Dec-2019 Methodist Le Bonheur Healthcare → Memphis-area hospitals n/a 1.5x 7.2x Methodist Le Bonheur Healthcare and the Memphis-area hospitals, recorded in December 2019 at 7.2x EBITDA and 1.5x revenue, shown as pending. In-market consolidation of this kind sits squarely on the regulatory critical path, which shapes timing more than price. Jul-2018 Apollo Global Management LLC → LifePoint Health Inc. n/a n/a 7.3x Apollo Global Management LLC announced the acquisition of LifePoint Health Inc. in July 2018 at 7.3x EBITDA. Sponsors participate selectively in this sector, usually with an operating partner, and the price here sits close to the middle of the recorded EBITDA… May-2017 Steward Health Care LLC → IASIS Healthcare LLC n/a n/a 8.2x Steward Health Care LLC announced the acquisition of IASIS Healthcare LLC in May 2017 at 8.2x EBITDA. Buying a multi-state operator outright is the route to density when tuck-ins are not available in the target service areas. Jun-2015 HealthSouth Corporation → Reliant Hospital Partners, LLC n/a n/a 9.8x HealthSouth Corporation announced the purchase of Reliant Hospital Partners, LLC in June 2015 at 9.8x EBITDA. Post-acute rehabilitation carries more predictable reimbursement and lower capital intensity than general acute care, and it sits at the upper end of this…

  20. 20
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This slide continues the list of precedent transactions with disclosed terms, newest first.

    This second page continues the list of 17 disclosed-terms transactions in this tier, out of 45 recorded, newest first, with multiples on LTM financials at announcement where disclosed. The same data-quality flags and omissions noted on the prior page apply here. Together, these two pages complete the transaction record behind the precedent benchmark.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 17 transactions with disclosed terms in this tier (45 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 52 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 28 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Jun-2015 Encompass Health Corp. → Reliant Hospital Partners, LLC n/a n/a 8.9x Jul-2013 Community Health Systems, Inc. → Health Management Associates, Inc. n/a n/a 8.2x Jun-2013 Tenet Healthcare Corporation → Vanguard Health Systems, Inc. n/a n/a 7.8x Jun-2010 Select Medical Holdings Corporation → Regency Hospital Company, L.L.C. n/a n/a 7.6x Jul-2006 Hercules Holding II, LLC → HCA Inc. n/a n/a 7.9x n/a n/a → HCA Healthcare, Inc. n/a 2.1x 10.2x Value shown as recorded in the filing; status defaulted announced. n/a n/a → HCA Healthcare, Inc. n/a 2.1x 10.2x Value shown as recorded in the filing; status defaulted announced. n/a n/a → Nutex Health Inc. n/a 1.6x 4.0x Value shown as recorded in the filing; status defaulted announced.

  21. 21
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    This slide explains the sources, assumptions and data-quality treatment underlying this report.

    This page sets out how this report was built: the sources, the valuation basis, and what was excluded from the peer set and the transaction list. Figures throughout draw on market data and consensus estimates, with company disclosures sourced via SEC filings where linked. That structure is what lets a client trace any number in this report back to where it came from.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice 21 VALUATION BASIS Primary valuation basis: EV / EBITDA on CY2027E consensus (8 of 8 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Hospitals and Health Systems and it clears the coverage gate with 8 of 8 companies (100%). EV / Revenue, P / E are carried as a cross-check. The set earns: 8 of the 8 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. DATA QUALITY & EXCLUSIONS 2 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 336 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (335) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  22. 22

    Across the 8 Listed Operators, the Higher Prices Sat with the Slower-Growing Names.

    This is the closing page restating the report's central finding and pointing to the companion tables.

    Across the 8 listed operators, the higher prices sat with the slower-growing names. The companion tables carry the full universe, the exclusion ledger and the complete source index for any figure a client wants to trace.

    Everything on this page

    Across the 8 Listed Operators, the Higher Prices Sat with the Slower-Growing Names. NeuraCap AI — Hospitals and Health Systems Coverage September 2026 · Prepared by NeuraCap AI · Confidential Hospitals and Health Systems Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 22

Sources and methodology

This report covers Hospitals and Health Systems (Health Care › Health Care Equipment and Services › Hospitals and Health Systems) with market data and consensus estimates as of September 28, 2026. The company universe is the 8 listed companies whose core business is Hospitals and Health Systems according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Ardent Health Inc. (ARDT), Auna S.A. (AUNA), Community Health Systems, Inc. (CYH), Encompass Health Corporation (EHC), HCA Healthcare, Inc. (HCA), Nutex Health, Inc. (NUTX), Tenet Healthcare Corporation (THC), Universal Health Services, Inc. (UHS). The market map groups them by business vertical — Behavioral and specialty hospital facilities: 8 companies (HCA, THC, EHC, UHS, CYH, ARDT, NUTX, AUNA). 8 of the 8 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Hospitals and Health Systems (Health Care › Health Care Equipment and Services › Hospitals and Health Systems) with market data and consensus estimates as of September 28, 2026. The company universe is the 8 listed companies whose core business is Hospitals and Health Systems according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Ardent Health Inc. (ARDT), Auna S.A. (AUNA), Community Health Systems, Inc. (CYH), Encompass Health Corporation (EHC), HCA Healthcare, Inc. (HCA), Nutex Health, Inc. (NUTX), Tenet Healthcare Corporation (THC), Universal Health Services, Inc. (UHS). The market map groups them by business vertical — Behavioral and specialty hospital facilities: 8 companies (HCA, THC, EHC, UHS, CYH, ARDT, NUTX, AUNA). 8 of the 8 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

2 records failed a validation gate and never feed a statistic in this report (2 excluded from aggregate). Each exclusion, with its reason: CYH — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CYH — Non-positive EPS; P/E is n/m (effect: excluded from aggregate)

Primary valuation basis and how it was chosen

Primary valuation basis: EV / EBITDA on CY2027E consensus (8 of 8 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Hospitals and Health Systems and it clears the coverage gate with 8 of 8 companies (100%). EV / Revenue, P / E are carried as a cross-check. The set earns: 8 of the 8 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 8 of 8 companies; EV / rEVenue: 8 of 8 companies; P/E: 7 of 8 companies. 1 company shows a non-meaningful P / E denominator and is excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥8.2x, Core 5.5x–8.2x, Discount <5.5x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 6.8x = median(ev_ebitda CY2027E) (8 rated companies) · 9.9x = median(ev_ebitda CY2027E) within Premium tier (n=2) · 6.8x = median(ev_ebitda CY2027E) within Core tier (n=4) · 4.6x = median(ev_ebitda CY2027E) within Discount tier (n=2) · 6.0x = median(ev_ebitda CY2027E) | growth ≥ 4% (n=4) · 7.6x = median(ev_ebitda CY2027E) | growth < 4% (n=4) · 8.3x = median(ev_ebitda CY2027E) | EBITDA margin ≥ 20% (n=4) · 5.2x = median(ev_ebitda CY2027E) | EBITDA margin < 20% (n=4) · 24% = median Rule of 40 score (revenue growth + EBITDA margin) (n=8) · 8.4x = median(ev_ebitda CY2027E) within balanced quadrant (n=2) · 8.3x = median(ev_ebitda CY2027E) within marginOnly quadrant (n=2) · 5.2x = median(ev_ebitda CY2027E) within growthOnly quadrant (n=2) · 6.3x = median(ev_ebitda CY2027E) within neither quadrant (n=2)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Hospitals and Health Systems recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 45 transactions were recorded for this industry; 17 are shown. 28 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 22 × deal value unit unresolved; 23 × no evidence record; 2 × duplicate precedent id; 4 × divestiture roles reassigned; 1 × financial target ev not meaningful. Case studies lead with the 1 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 340 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Hospitals and Health Systems?

Company valuation reports run the same method against a single business — public or private.